Quick Answer
Organon & Co. reported Total Revenue of $6.22 billion for fiscal year 2025.
Organon & Co. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.22B -2.9% |
$6.40B +2.2% |
$6.26B +1.4% |
$6.17B -2.1% |
$6.30B -3.5% |
$6.53B -16.0% |
| Net Income | $187.00M -78.4% |
$864.00M -15.5% |
$1.02B +11.6% |
$917.00M -32.1% |
$1.35B -37.5% |
$2.16B -32.9% |
| Diluted EPS | $0.72 -78.4% |
$3.33 -16.5% |
$3.99 +11.1% |
$3.59 -32.4% |
$5.31 -37.7% |
$8.52 -32.9% |
| Total Assets | $12.87B -1.8% |
$13.10B +8.6% |
$12.06B +10.1% |
$10.96B +2.6% |
$10.68B +5.7% |
$10.11B |
| Cash and Equivalents | $574.00M -15.0% |
$675.00M -2.6% |
$693.00M -1.8% |
$706.00M -4.2% |
$737.00M +6041.7% |
$12.00M |
| Long-Term Debt | $8.63B -2.6% |
$8.86B +1.2% |
$8.75B -1.7% |
$8.90B -2.4% |
$9.12B | $0.00 |
| Stockholders Equity | $752.00M +59.3% |
$472.00M +774.3% |
-$70.00M +92.2% |
-$892.00M +40.8% |
-$1.51B -127.5% |
$5.49B -22.0% |
| R&D Expense | — | — | — | — | $443.00M +111.0% |
$210.00M -4.5% |
| Gross Profit | $3.31B -10.8% |
$3.71B -0.9% |
$3.75B -3.4% |
$3.88B | — | — |
| Shares Outstanding | 260.32M +1.0% |
257.80M +0.9% |
255.63M +0.5% |
254.37M +0.3% |
253.55M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.60B | +1.3% | +0.5% |
| Net Income | September 30, 2025 | $160.00M | -55.4% | +10.3% |
| Diluted EPS | September 30, 2025 | $0.61 | -55.8% | +8.9% |
| Total Assets | September 30, 2025 | $13.55B | +6.3% | +0.4% |
| Cash and Equivalents | September 30, 2025 | $672.00M | -11.9% | +12.2% |
| Long-Term Debt | September 30, 2025 | $8.78B | +0.5% | +0.0% |
| Stockholders Equity | September 30, 2025 | $906.00M | +83.8% | +23.6% |
| R&D Expense | March 31, 2022 | $96.00M | +43.3% | -13.5% |
| Gross Profit | September 30, 2025 | $857.00M | -7.2% | -1.9% |
| Shares Outstanding | September 30, 2025 | 259.98M | +0.9% | +0.0% |
- Organon & Co. reported Total Revenue of $6.22 billion for fiscal year 2025.
- Organon & Co. showed a decrease of -2.9% in Total Revenue compared to the prior fiscal year.
- Organon & Co. reported Net Income of $187.00 million for fiscal year 2025.
- Organon & Co. showed a decrease of -78.4% in Net Income compared to the prior fiscal year.
- Organon & Co. reported Diluted EPS of $0.72 per share for fiscal year 2025.
- Organon & Co. showed a decrease of -78.4% in Diluted EPS compared to the prior fiscal year.
- Organon & Co. reported Total Assets of $12.87 billion for fiscal year 2025.
- Organon & Co. showed a decrease of -1.8% in Total Assets compared to the prior fiscal year.
- Organon & Co. reported Cash and Equivalents of $574.00 million for fiscal year 2025.
- Organon & Co. showed a decrease of -15.0% in Cash and Equivalents compared to the prior fiscal year.
- Organon & Co. reported Long-Term Debt of $8.63 billion for fiscal year 2025.
- Organon & Co. showed a decrease of -2.6% in Long-Term Debt compared to the prior fiscal year.
- Organon & Co. reported Stockholders Equity of $752.00 million for fiscal year 2025.
- Organon & Co. showed an increase of +59.3% in Stockholders Equity compared to the prior fiscal year.
- Organon & Co. reported R&D Expense of $443.00 million for fiscal year 2021.
- Organon & Co. showed an increase of +111.0% in R&D Expense compared to the prior fiscal year.
- Organon & Co. reported Gross Profit of $3.31 billion for fiscal year 2025.
- Organon & Co. showed a decrease of -10.8% in Gross Profit compared to the prior fiscal year.
- Organon & Co. reported Shares Outstanding of 260.32 million shares for fiscal year 2025.
- Organon & Co. showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: